Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB

(UCB)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 05/25 03:30:00 pm
82.84 EUR   +1.32%
11:33aUCB : S.A. - Acquisitions of own shares and Disposals of own shares
AQ
05/04UCB : Ex-dividend day for final dividend
FA
05/01UCB : S.A. - Acquisitions of own shares and Disposals of own shares
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
05/19/2020 05/20/2020 05/21/2020 05/22/2020 05/25/2020 Date
82.92(c) 81.84(c) 80.72(c) 81.76(c) 82.84(c) Last
415 095 411 317 303 952 4 420 615 167 676 Volume
-0.91% -1.30% -1.37% +1.29% +1.32% Change
More quotes
Financials
Sales 2020 5 192 M 5 665 M 5 665 M
Net income 2020 819 M 894 M 894 M
Net Debt 2020 1 379 M 1 504 M 1 504 M
P/E ratio 2020 19,9x
Yield 2020 1,57%
Sales 2021 5 450 M 5 946 M 5 946 M
Net income 2021 991 M 1 081 M 1 081 M
Net Debt 2021 717 M 783 M 783 M
P/E ratio 2021 16,5x
Yield 2021 1,63%
Capitalization 15 617 M 17 018 M 17 040 M
EV / Sales 2020 3,27x
EV / Sales 2021 3,00x
Nbr of Employees 7 160
Free-Float 59,0%
More Financials
Company
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. 
Sector
Pharmaceuticals
Calendar
06/02Presentation
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
11:33aUCB : S.A. - Acquisitions of own shares and Disposals of own shares
AQ
05/04UCB : Ex-dividend day for final dividend
FA
05/01UCB : S.A. - Acquisitions of own shares and Disposals of own shares
AQ
04/30UCB : General Meeting of Shareholders
PU
04/24UCB : S.A. - Acquisitions of own shares and Disposals of own shares
AQ
04/13UCB : Acquisitions of own shares and Disposals of own shares
AQ
04/10UCB : General Meeting of Shareholders
PU
04/06UCB : S.A. - Acquisitions of own shares and Disposals of own shares
AQ
04/02UCB : completes the acquisition of Ra Pharmaceuticals – to deliver differe..
PU
03/27UCB SA/NV : Convening notice to the general meeting of shareholders
GL
03/27UCB : Mixed general shareholder meeting
CO
03/25UCB : Disposal of own shares
AQ
03/25UCB : Share Repurchase Program to cover UCB's Long Term Incentive Plans for its ..
AQ
03/24UCB : Share Repurchase Program to cover UCB's Long Term Incentive …
PU
03/18UCB : Disposal of own shares
PU
More news
News in other languages on UCB
05/04UCB : Ex-dividend day for final dividend
04/09AVIS D'ANALYSTES DU JOUR : Adidas, Amundi, Crédit Agricole, Ipsen, Sika, Tarkett..
03/13UCB : baisse contenue après la déception Padsevonil
03/06UCB : cession de droits sur Alprostadil dans plusieurs pays
02/26AVIS D'ANALYSTES DU JOUR : Arkema, Pernod Ricard, Iliad, Rémy Cointreau, Vivendi..
More news
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 91,22 €
Last Close Price 82,84 €
Spread / Highest target 30,4%
Spread / Average Target 10,1%
Spread / Lowest Target -11,9%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Detlef Thielgen Chief Financial Officer, EVP & Head-Development
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Dhavalkumar Patel Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
UCB16.84%16 791
CSL LIMITED8.16%86 208
BIOGEN INC.2.63%49 695
SAMSUNG BIOLOGICS CO.,LTD.45.96%32 910
ALEXION PHARMACEUTICALS-6.15%22 414
WUXI BIOLOGICS (CAYMAN) INC.28.23%21 053